Literature DB >> 26351224

Pediatric infratentorial ganglioglioma.

Stephanie Puget1,2,3, Awad Alshehri4,5, Kevin Beccaria4,5, Thomas Blauwblomme4,5, Giovanna Paternoster4,5, Syril James4,5, Federico Dirocco4,5, Christelle Dufour6, Michel Zerah4,5, Pascale Varlet7, Christian Sainte-Rose4,5.   

Abstract

PURPOSE: Pediatric infratentorial gangliogliomas are exceedingly rare tumors; thus, the factors affecting their outcome are poorly understood and their optimal management has still to be defined.
METHODS: We reviewed the literature on pediatric gangliogliomas with a focus on those located in the posterior fossa to study treatment and outcome data. We added to this review some of our clinical cases.
RESULTS: We found 100 and 80 cases of brainstem and cerebellar pediatric ganglioglioma, respectively, in our literature review. The surgical management varied from biopsy to gross total resection, and adjuvant treatment was given after incomplete resection or at time of progression. A gross total resection should be attempted to remove the contrast enhancing part of the tumor, which may be possible in most of the cerebellar gangliogliomas and some of the brainstem lesions. The cervicomedullary ganglioglioma seems to be the most infiltrative and least amenable to complete resection. Chemotherapy has a limited role and BRAF mutation was reported in 38 to 54 % of cases. The use of radiotherapy exposes the patient to a risk of malignant transformation and should be reserved for unresectable tumors which progress.
CONCLUSION: Pediatric posterior fossa gangliogliomas are rare and challenging tumors due to their frequent infiltrative component involving the brainstem. To date, adjuvant therapy has a limited role that may evolve with time thanks to the use of targeted therapies against BRAF mutation. The surgical resection of well-defined contrast enhancing parts should be attempted even in staged surgeries and balanced with the risks of neurological deterioration.

Entities:  

Keywords:  Brainstem; Cerebellum; Ganglioglioma; Pediatric; Posterior fossa

Mesh:

Year:  2015        PMID: 26351224     DOI: 10.1007/s00381-015-2860-x

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  78 in total

1.  Malignant and benign ganglioglioma: a pathological and molecular study.

Authors:  Ajay Pandita; Anandh Balasubramaniam; Richard Perrin; Patrick Shannon; Abhijit Guha
Journal:  Neuro Oncol       Date:  2007-01-26       Impact factor: 12.300

Review 2.  Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas.

Authors:  C S Rumana; A B Valadka
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Posterior fossa ganglioglioma--an unusual cause of hearing loss.

Authors:  R S Dhillon
Journal:  J Laryngol Otol       Date:  1987-07       Impact factor: 1.469

4.  Cerebellar gliomas in children with NF1: pathology and surgery.

Authors:  M Vinchon; G Soto-Ares; M M Ruchoux; P Dhellemmes
Journal:  Childs Nerv Syst       Date:  2000-07       Impact factor: 1.475

5.  Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery.

Authors:  So-Hyang Im; Chun Kee Chung; Byung-Kyu Cho; Kyu-Chang Wang; In-Kyu Yu; In Chan Song; Gi Jeong Cheon; Dong Soo Lee; Na-Rae Kim; Je G Chi
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.

Authors:  Céline Chappé; Laetitia Padovani; Didier Scavarda; Fabien Forest; Isabelle Nanni-Metellus; Anderson Loundou; Sandy Mercurio; Frédéric Fina; Gabriel Lena; Carole Colin; Dominique Figarella-Branger
Journal:  Brain Pathol       Date:  2013-03-20       Impact factor: 6.508

7.  Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.

Authors:  Andrew M Donson; Bette K Kleinschmidt-DeMasters; Dara L Aisner; Lynne T Bemis; Diane K Birks; Jean M Mulcahy Levy; Amy A Smith; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  Brain Pathol       Date:  2013-12-23       Impact factor: 6.508

8.  Brainstem gangliogliomas: a retrospective series.

Authors:  Si Zhang; Xiang Wang; Xuesong Liu; Yan Ju; Xuhui Hui
Journal:  J Neurosurg       Date:  2013-02-01       Impact factor: 5.115

9.  Gangliogliomas in children. A clinicopathological study.

Authors:  E Garrido; L F Becker; H J Hoffman; E B Hendrick; R Humphreys
Journal:  Childs Brain       Date:  1978

10.  Ganglioglioma: 13 years of experience.

Authors:  S F Haddad; S A Moore; A H Menezes; J C VanGilder
Journal:  Neurosurgery       Date:  1992-08       Impact factor: 4.654

View more
  4 in total

1.  Ganglioglioma in children and young adults: single institution experience and review of the literature.

Authors:  Wafik Zaky; Shekhar S Patil; Minjeong Park; Diane Liu; Wei-Lien Wang; Khalida M Wani; Susana Calle; Leena Ketonen; Soumen Khatua
Journal:  J Neurooncol       Date:  2018-06-07       Impact factor: 4.130

2.  Suprasellar ganglioglioma presenting as a middle cerebral artery infarction.

Authors:  Laura Pastor; Sara Iglesias; Bienvenido Ros; Bernardo Weil; María Isabel Martínez-León; Miguel Ángel Arráez
Journal:  Childs Nerv Syst       Date:  2019-07-09       Impact factor: 1.475

3.  Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Arnoldo Piccardo; Nathalie L Albert; Lise Borgwardt; Frederic H Fahey; Darren Hargrave; Norbert Galldiks; Nina Jehanno; Lars Kurch; Ian Law; Ruth Lim; Egesta Lopci; Lisbeth Marner; Giovanni Morana; Tina Young Poussaint; Victor J Seghers; Barry L Shulkin; Katherine E Warren; Tatjana Traub-Weidinger; Pietro Zucchetta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-10       Impact factor: 10.057

4.  A Rare Case of a Congenital Nasopharyngeal Ganglioglioma With Dyspnea in a 1-Month-Old Male Infant: A Case Report.

Authors:  He Zhao; Zhiwei Cao; Zhaowei Gu
Journal:  Front Pediatr       Date:  2021-06-10       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.